TSE:ONC Oncolytics Biotech (ONC) Stock Price, News & Analysis C$14.90 -0.20 (-1.32%) As of 09/3/2025 Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsEarningsHeadlinesInsider TradesBuy This Stock About Oncolytics Biotech Stock (TSE:ONC) Get Oncolytics Biotech alerts:Sign Up Key Stats Today's RangeC$14.90▼C$14.9050-Day RangeC$14.90▼C$14.9052-Week RangeC$0.44▼C$2.08Volume280 shsAverage Volume169,589 shsMarket CapitalizationC$1.50 billionP/E RatioN/ADividend Yield0.31%Price TargetN/AConsensus RatingStrong Buy Company Overview Oncolytics Biotech Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma. It has a co-development agreement with Merck KGaA and Pfizer Inc. to co-develop pelareorep, as well as with Roche Holding AG. The company was incorporated in 1998 and is headquartered in Calgary, Canada. Read More Oncolytics Biotech Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks0th Percentile Overall ScoreONC MarketRank™: Oncolytics Biotech scored higher than 0% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion0.0 / 5Analyst RatingStrong Buy Amount of Analyst CoverageOncolytics Biotech has received no research coverage in the past 90 days.Read more about Oncolytics Biotech's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Oncolytics Biotech is -40.27, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Oncolytics Biotech is -40.27, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioOncolytics Biotech has a P/B Ratio of 222.68. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short InterestN/AShort Interest LevelN/A Short InterestThere is no current short interest data available for ONC. Dividend0.0 / 5Dividend StrengthWeak Dividend YieldOncolytics Biotech has a dividend yield of 0.31%, which is in the bottom 25% of all stocks that pay dividends.Dividend GrowthOncolytics Biotech does not have a long track record of dividend growth.Read more about Oncolytics Biotech's dividend. News and Social Media0.6 / 5News SentimentN/A News Coverage This WeekMarketBeat has tracked 1 news article for Oncolytics Biotech this week, compared to 2 articles on an average week.Search Interest7 people have searched for ONC on MarketBeat in the last 30 days. This is an increase of 17% compared to the previous 30 days. Company Ownership0.1 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Oncolytics Biotech insiders have not sold or bought any company stock.Percentage Held by Insiders3.82% of the stock of Oncolytics Biotech is held by insiders.Percentage Held by Institutions0.07% of the stock of Oncolytics Biotech is held by institutions.Read more about Oncolytics Biotech's insider trading history. Receive ONC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Oncolytics Biotech and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ONC Stock News HeadlinesOncolytics Biotech (TSE:ONC) Stock Price Passes Above 200 Day Moving Average - What's Next?August 4 at 3:01 AM | americanbankingnews.comOncolytics Biotech (TSE:ONC) Share Price Passes Above Two Hundred Day Moving Average - Here's What HappenedJuly 25, 2026 | americanbankingnews.comThe $15 Gold Fund That Pays Up to $1,152/MonthGold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying out up to $1,152 a month to regular investors - no mining stocks, no options, no physical metal required. Chief Income Strategist Tim Plaehn calls it a breakthrough strategy that transforms gold's rally into reliable monthly payouts. The next distribution is just days away.August 4 at 1:00 AM | Investors Alley (Ad)Viral immunotherapy gets FDA fast track for anal cancer patients without optionsJuly 20, 2026 | msn.comOncolytics Biotech Shares Climb Ahead of Planned FDA Meeting on REO 033 Trial (ONCY)July 13, 2026 | finance.yahoo.comOncolytics Biotech Shares Rise on FDA Meeting Plan, Trial Progress in Colorectal CancerJuly 13, 2026 | marketwatch.comFive Companies Whose Innovations Could Challenge Entire IndustriesJuly 11, 2026 | thestreet.comAnalysts’ Opinions Are Mixed on These Healthcare Stocks: Oncolytics Biotech (ONCY), Stryker (SYK) and Alkermes (ALKS)June 19, 2026 | theglobeandmail.comSee More Headlines ONC Stock Analysis - Frequently Asked Questions How have ONC shares performed this year? Oncolytics Biotech's stock was trading at C$14.90 on January 1st, 2026. Since then, ONC stock has increased by 0.0% and is now trading at C$14.90. How were Oncolytics Biotech's earnings last quarter? Oncolytics Biotech Inc. (TSE:ONC) issued its quarterly earnings data on Tuesday, November, 12th. The company reported ($0.12) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.11) by $0.01. How do I buy shares of Oncolytics Biotech? Shares of ONC stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers. What other stocks do shareholders of Oncolytics Biotech own? Based on aggregate information from My MarketBeat watchlists, some other companies that Oncolytics Biotech investors own include Oncolytics Biotech (ONCY), Ballard Power Systems (BLDP), Resverlogix (RVX), Birchcliff Energy (BIR), Enbridge (ENB) and Gold.com (GOLD). Company Calendar Last Earnings11/12/2024Today8/04/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeTSE SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolTSE:ONC CIKN/A Webwww.oncolyticsbiotech.com Phone+1-403-6707380FaxN/AEmployees29Year FoundedN/AProfitability EPS (Trailing Twelve Months)C($0.37) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-C$27.66 million Net MarginsN/A Pretax MarginN/A Return on Equity-204.28% Return on Assets-71.33% Debt Debt-to-Equity Ratio14.58 Current Ratio2.88 Quick Ratio8.86 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowC$3.53 per share Price / Cash Flow4.22 Book ValueC$0.07 per share Price / Book222.68Miscellaneous Outstanding Shares100,361,000Free FloatN/AMarket CapC$1.50 billion OptionableNot Optionable Beta0.80 10 Best Stocks to Own - Summer 2026Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment. Get This Free Report This page (TSE:ONC) was last updated on 8/4/2026 by MarketBeat.com Staff. From Our PartnersCentral banks bought 710 tonnes - this fund pays monthlyGold is hitting new highs, fueled by tariffs and record central bank demand - 710 tonnes per quarter. JPMorgan...Investors Alley | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | Sponsored1 Stock to Own by July 31stA scheduled announcement on July 31st could reshuffle the stock market's winners and losers - and one lesser-k...Chaikin Analytics | SponsoredHe bet half his $9 billion on ONE stockOne of the most successful fund managers of the past 50 years put more than $4.5 billion - over half his fund ...Stansberry Research | SponsoredThe dollar reset no one told you aboutPorter Stansberry says a dollar reset is underway - one that has happened only once before in America's 250-ye...Porter & Company | SponsoredYour book attachedBill Poulos is giving away his 'Simple Options Trading For Beginners' book at no cost - normally $29.97. It ou...Profits Run | SponsoredWhere to Put $100 Before Trump's New Tech Law Rolls OutThe Financial Times says a new tech law puts America 'on the verge of a financial revolution.' Yahoo Finance e...Brownstone Research | SponsoredMan who Predicted Trump 2016 Win: “Prepare for Mid-Term Meltdown”In 2016, major election models gave Hillary Clinton a 99% chance of winning - but former CIA and Pentagon advi...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Oncolytics Biotech Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Oncolytics Biotech With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
